EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas aeruginosa

Katherine D Soto, Manuel Alcalde-Rico, Juan A Ugalde, Jorge Olivares-Pacheco, Valeria Quiroz, Bárbara Brito, Lina M Rivas, José M Munita, Patricia C García, Aniela Wozniak

Frontiers in Cellular and Infection Microbiology · 05.06.2024 · 14

DOI: 10.3389/fcimb.2024.1410834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, online erschienen am 05.06.2024. Verfasst von Katherine D Soto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Microbiology, Department of Clinical Laboratories; Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. Hauptthemen laut MEDLINE: Bacterial Proteins, Ceftazidime, Drug Resistance, Multiple, Bacterial, Pseudomonas aeruginosa. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ceftazidime/avibactam (CZA) is indicated against multidrug-resistant Pseudomonas aeruginosa , particularly those that are carbapenem resistant. CZA resistance in P. aeruginosa producing PER, a class A extended-spectrum β-lactamase, has been well documented in vitro . However, data regarding clinical isolates are scarce. Our aim was to analyze the contribution of PER to CZA resistance in non-carbapenemase-producing P. aeruginosa clinical isolates that were ceftazidime and/or carbapenem non-susceptible.

Methods

Antimicrobial susceptibility was determined through agar dilution and broth microdilution, while bla PER gene was screened through PCR. All PER-positive isolates and five PER-negative isolates were analyzed through Whole Genome Sequencing. The mutational resistome associated to CZA resistance was determined through sequence analysis of genes coding for PBPs 1b, 3 and 4, MexAB-OprM regulators MexZ, MexR, NalC and NalD, AmpC regulators AmpD and AmpR, and OprD porin. Loss of bla PER-3 gene was induced in a PER-positive isolate by successive passages at 43°C without antibiotics.

Results

Twenty-six of 287 isolates studied (9.1%) were CZA-resistant. Thirteen of 26 CZA-resistant isolates (50%) carried bla PER . One isolate carried bla PER but was CZA-susceptible. PER-producing isolates had significantly higher MICs for CZA, amikacin, gentamicin, ceftazidime, meropenem and ciprofloxacin than non-PER-producing isolates. All PER-producing isolates were ST309 and their bla PER-3 gene was associated to ISCR1, an insertion sequence known to mobilize adjacent DNA. PER-negative isolates were classified as ST41, ST235 (two isolates), ST395 and ST253. PER-negative isolates carried genes for narrow-spectrum β-lactamases and the mutational resistome showed that all isolates had one major alteration in at least one of the genes analyzed. Loss of bla PER-3 gene restored susceptibility to CZA, ceftolozane/tazobactam and other β-lactamsin the in vitro evolved isolate.

Discussion

PER-3-producing ST309 P. aeruginosa is a successful multidrug-resistant clone with bla PER-3 gene implicated in resistance to CZA and other β-lactams.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bacterial ProteinsCeftazidimeDrug Resistance, Multiple, BacterialPseudomonas aeruginosaPseudomonas InfectionsHumansAnti-Bacterial AgentsAzabicyclo Compoundsbeta-LactamasesChileDrug CombinationsMicrobial Sensitivity TestsMutationWhole Genome Sequencing

Stichwörter der Autor:innen

PER-3 extended-spectrum β-lactamasePseudomonas aeruginosablaPER-3 geneceftazidime/avibactam resistancemutations conferring CZA resistance

Substanzen

Anti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsBacterial Proteinsbeta-LactamasescarbapenemaseCeftazidimeDrug Combinations

Autor:innen und Institutionen

  • Laboratory of Microbiology, Department of Clinical Laboratories; Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Instituto de Ciencias e Innovación en Medicina (ICIM), Facultad de Medicina, Universidad del Desarrollo. Millennium Initiative for Collaborative Research on Bacterial Resistance (MICROB-R), Santiago, Chile.
  • Grupo de Resistencia Antimicrobiana en Bacterias Patógenas y Ambientales (GRABPA), Instituto de Biología, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile.
  • Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen Macarena, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Sevilla, Sevilla, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain.
  • Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile.

Zitieren

APA

Soto, K. D., Alcalde-Rico, M., Ugalde, J. A., Olivares-Pacheco, J., Quiroz, V., Brito, B., Rivas, L. M., Munita, J. M., García, P. C., & Wozniak, A. (2024). Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology, 14. https://doi.org/10.3389/fcimb.2024.1410834

Vancouver

Soto KD, Alcalde-Rico M, Ugalde JA, Olivares-Pacheco J, Quiroz V, Brito B, et al. Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas aeruginosa. Frontiers in Cellular and Infection Microbiology. 2024;14. doi:10.3389/fcimb.2024.1410834

BibTeX
@article{Soto2024,
  author = {Soto, Katherine D and Alcalde-Rico, Manuel and Ugalde, Juan A and Olivares-Pacheco, Jorge and Quiroz, Valeria and Brito, Bárbara and Rivas, Lina M and Munita, José M and García, Patricia C and Wozniak, Aniela},
  title = {Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas aeruginosa},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  volume = {14},
  doi = {10.3389/fcimb.2024.1410834}
}
Kostenlos starten →